Kenneth D. Steinsapir receives rare USPTO patent for Microdroplet BOTOX

Kenneth D. Steinsapir, M.D., Inc. has been issued a rare patent (US 7,846,457 B2) by The United States Patent and Trademark Office for the invention of a breakthrough method for administering cosmetic botulinum toxin. The patent for Microdroplet™ botulinum toxin, a nonsurgical cosmetic facial treatment that improves upon standard BOTOX® treatments, was officially approved on December 7, 2010. The patent holder and inventor is Dr. Kenneth D. Steinsapir, a cosmetic surgeon in Los Angeles specializing in surgery and minimally invasive treatments that enhance facial features with natural-looking results.

Microdroplet™ BOTOX® utilizes tiny microdroplet volumes of botulinum toxin injected into the facial skin at a precise depth and positioning. This controlled placement balances the "tug of war" between the muscles that elevate and pull down the eyebrows. The treatment avoids side effects like BOTOX® "drift" and "forehead freeze."

Many high-profile professionals seek Microdroplet™ BOTOX® so they can benefit without the unwanted side effects of other treatments; as word has spread, growing numbers of patients fly into Los Angeles for this service.

Dr. Steinsapir reports, "I have been treating patients with BOTOX® since 1988, and early on I recognized the need for an improved approach to cosmetic treatment by carefully listening to the concerns of my patients." This vast experience crystallized into the Microdroplet™ botulinum toxin method in 2006, which is the basis for the U.S. Patent.

"Natural outcomes are vital to a successful and satisfying cosmetic treatment experience," says Dr. Steinsapir. "Microdroplet BOTOX can improve the appearance because it works on select muscles to attain and improve overall facial balance. It's an important option for individuals who seek cosmetic improvement without surgery and an essential alternative to current treatment methods."

"There is little doubt that this new method will become the predominant method for administering botulinum toxin," observes Dr. Steinsapir.

Source: Kenneth D. Steinsapir

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Low-carb diet may improve beta-cell function in type 2 diabetes patients